Welcome to our dedicated page for Sonendo SEC filings (Ticker: SONX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Sonendo, Inc. (SONX) is intended to provide investors with access to the company’s regulatory disclosures once available, including annual and quarterly reports, current reports and ownership filings. While no specific SEC filings are listed in the provided data, Sonendo’s public news releases reference information that is typically detailed in formal filings, such as revenue by product category, gross margin, operating loss, adjusted EBITDA loss and free cash flow burn.
Through its communications, Sonendo identifies itself as a commercial-stage medical technology and dental technology company that develops and manufactures the GentleWave System for tooth decay and root canal treatment. In SEC reports such as a Form 10-K or Form 10-Q, investors would generally expect to find more detail on this business model, including segment information for GentleWave console sales, procedure instruments and other product revenue, as well as discussions of restructuring activities, liquidity and capital resources.
Sonendo’s press releases also reference non-GAAP financial measures like adjusted gross margin, adjusted EBITDA loss and free cash flow burn, and point to additional explanations in Form 8-K filings. Formal SEC filings typically describe how these non-GAAP measures are calculated and reconciled to GAAP results, along with management’s rationale for using them.
For corporate actions and strategic transactions, such as the Asset Purchase Agreement to acquire Biolase assets through a bankruptcy court-supervised process, related details and risk factors are commonly addressed in current reports and other SEC submissions. On this page, Stock Titan’s tools can pair real-time EDGAR updates with AI-powered summaries to help explain the key points in Sonendo’s 10-K, 10-Q, 8-K and, when applicable, insider transaction reports on Form 4, making the company’s regulatory history easier to review and understand.
First Wilshire Securities Management, Inc. filed an amended Schedule 13G stating it now beneficially owns 0 shares of Sonendo Inc. common stock, representing 0.0% of the class. The firm reports no sole or shared voting power and no sole or shared dispositive power over any Sonendo shares.
The filer certifies that any securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Sonendo. The amendment reflects that First Wilshire is no longer a beneficial owner of Sonendo’s equity securities under reporting thresholds.